PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
|Articles|September 2, 2011
Strategic Approach to Glycoprotein and Glycosylation Analysis Intertek and NIBRT Seminar
Intertek and NIBRT are pleased to announce two free seminars covering the Characterisation of Glycoproteins.
Advertisement
Intertek and NIBRT are pleased to announce two free seminars covering the Characterisation of Glycoproteins.
To request the agenda contact us now at
The presentations will be delivered by experts in their field; Ashleigh Wake Intertek’s Biotechnology Team Leader and Professor Pauline Rudd, a leading authority on protein glycosylation.
This seminar would be of interest to professionals working in protein therapeutic development and manufacturing.
Agenda:
- Introduction to the Intertek / NIBRT strategic collaboration
- A Strategic approach to glycoprotein analysis – Ashleigh Wake, Intertek Biotechnology Team Leader
- A systematic approach to protein glycosylation analysis – Prof. Pauline Rudd, NIBRT
Dates:
22nd September 2011, Intertek, Manchester, UK
23rd September 2011, NIBRT, Dublin, Ireland
Register your interest
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
2
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
3
Symptomatic Dermographism: Novartis Lands Remibrutinib Label Expansion
4
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
5